Eloxx Pharmaceuticals Inc   (ELOX)
Other Ticker:  
Price: $0.8895 $0.09 11.174%
Day's High: $0.8895 Week Perf: 2.24 %
Day's Low: $ 0.87 30 Day Perf: 6.53 %
Volume (M): 5 52 Wk High: $ 10.90
Volume (M$): $ 5 52 Wk Avg: $3.98
Open: $0.87 52 Wk Low: $0.40

 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 3
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -32
 Cash Flow (TTM) (Millions $) -20
 Capital Exp. (TTM) (Millions $) 0

Eloxx Pharmaceuticals Inc
Eloxx Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics for genetic diseases. The company focuses on genetic diseases caused by nonsense mutations, which are mutations that prematurely stop the production of functional proteins. Eloxx develops small molecule drugs called ribosomal selective glycosides (RSGs) that can enable the ribosome to bypass the mutated part of the gene and continue protein synthesis, leading to the production of functional proteins. The company's lead product candidate, ELX-02, is being developed to treat cystic fibrosis and other diseases caused by nonsense mutations. Eloxx Pharmaceuticals aims to provide innovative treatment options for patients with genetic diseases where limited therapeutic options currently exist.

   Company Address: 480 Arsenal Way Watertown 2472 MA
   Company Phone Number: 577-5300   Stock Exchange / Ticker: NASDAQ ELOX
   ELOX is expected to report next financial results on March 30, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Eloxx Pharmaceuticals Inc

ELOX Raises the Bar: Showcasing their Remarkable Third Quarter Success Amidst Tough Competition

The latest financial figures from the third quarter of 2023 indicate a struggling performance for Eloxx Pharmaceuticals Inc, a renowned player in the Biotechnology & Pharmaceuticals sector. Despite efforts to increase revenue streams, the company continues to grapple with significant operating shortfalls and declining stock performance. A detailed analysis of their financial numbers suggests a bearish outlook for Eloxx Pharmaceuticals Inc in the near future.
Operating Shortfall and Revenue Concerns:
During the July to September 2023 quarter, Eloxx Pharmaceuticals Inc reported an operating shortfall of $-3.637 million. Notably, the company did not disclose any revenue, which raises concerns about its ability to generate substantial earnings. This lack of revenue visibility is unsettling as it indicates potential hurdles in sustaining the business and meeting investor expectations.
Cost-Effectiveness and Loss Reduction Efforts:
In comparison to the corresponding period in the previous year, Eloxx Pharmaceuticals Inc showcased some improvement in cost-effectiveness. The operating shortfall decreased from $-7.142 million in the third quarter of 2022 to $-3.592 million in the third quarter of 2023. Although this reduction in losses is encouraging, it is overshadowed by the fact that the company is still struggling to achieve profitability.
Declining Stock Performance:
The brutal truth lies in the stock market performance of Eloxx Pharmaceuticals Inc. Over the past five trading days, the company's shares have witnessed a decline of -8.15%. This downward spiral further accentuates the bearish sentiment surrounding the stock. Furthermore, the year-to-date performance stands at a disheartening -57.05%, indicating a significant erosion of investor confidence.

Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals Inc Makes Strides Towards Recovery With Improved Operating Situation, Reporting an Operating Shortfall of $-4.14 Million

The stock market is an ever-changing and dynamic entity, constantly influenced by various factors that can make or break a company's success. In the midst of the April to June 2023 reporting season, we have seen a multitude of companies announcing their respective earnings. Among the notable participants in this season are the constituents of the Biotechnology & Pharmaceuticals industry, and today we focus on Eloxx Pharmaceuticals Inc.
Eloxx Pharmaceuticals Inc, a prominent player in the industry, has recently reported an operating shortfall of $-4.14 million for the April to June 30, 2023 time-frame. This figure may raise some eyebrows, but it is essential to analyze it in the context of the previous year's performance. Surprisingly, Eloxx Pharmaceuticals Inc has shown a significant improvement in their operating situation compared to the same period last year.

Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals Inc Soars to New Heights, Achieving an Astounding $-5.483 Million Improvement in First Quarter of 2023

Eloxx Pharmaceuticals Inc is a biotechnology company that specializes in the development of treatments for rare genetic diseases caused by non-sense mutations. The company is headquartered in Waltham, Massachusetts and has operations in the United States, Europe, and Israel. Eloxx Pharmaceuticals Inc's focus is on discovering and developing new drugs that target specific genetic mutations that cause diseases.
The biotechnology and pharmaceuticals sector has been a growing industry in recent years, with many big players such as Pfizer, Moderna, and Johnson & Johnson dominating the market. However, there has also been a surge in the number of smaller corporations, like Eloxx Pharmaceuticals Inc, entering the market with innovative research and development.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com